These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19153442)

  • 1. Diverse DES usage: Indian perspective and data.
    Bhatia V; Kaul U
    Indian Heart J; 2007; 59(2 Suppl B):B9-15. PubMed ID: 19153442
    [No Abstract]   [Full Text] [Related]  

  • 2. Current opinions on usage and regulation of drug-eluting stents in India: results of a nation-wide survey of Indian cardiologists.
    Bahl VK; Narang R
    Indian Heart J; 2005; 57(4):355-9. PubMed ID: 16350687
    [No Abstract]   [Full Text] [Related]  

  • 3. Stent sales slide. Hospitals using fewer drug-eluting devices.
    Rhea S
    Mod Healthc; 2007 Oct; 37(42):14-5. PubMed ID: 18027478
    [No Abstract]   [Full Text] [Related]  

  • 4. The drug-eluting stent (DES) market.
    Waksman R
    Cardiovasc Revasc Med; 2008; 9(3):131. PubMed ID: 18606374
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.
    Goeree R; Bowen JM; Blackhouse G; Lazzam C; Cohen E; Chiu M; Hopkins R; Tarride JE; Tu JV
    Int J Technol Assess Health Care; 2009 Apr; 25(2):196-207. PubMed ID: 19331710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent landmark trials in cardiology 2008.
    Jain P; Bhandari S
    Indian Heart J; 2008; 60(4):372-6. PubMed ID: 19242023
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies.
    Kirtane AJ; Gupta A; Iyengar S; Moses JW; Leon MB; Applegate R; Brodie B; Hannan E; Harjai K; Jensen LO; Park SJ; Perry R; Racz M; Saia F; Tu JV; Waksman R; Lansky AJ; Mehran R; Stone GW
    Circulation; 2009 Jun; 119(25):3198-206. PubMed ID: 19528338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical appraisal of the safety and efficacy of drug-eluting stents.
    Maluenda G; Lemesle G; Waksman R
    Clin Pharmacol Ther; 2009 May; 85(5):474-80. PubMed ID: 19279567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting stents: a comprehensive appraisal.
    Butt M; Connolly D; Lip GY
    Future Cardiol; 2009 Mar; 5(2):141-57. PubMed ID: 19371189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis.
    Filion KB; Roy AM; Baboushkin T; Rinfret S; Eisenberg MJ
    Am J Cardiol; 2009 Feb; 103(3):338-44. PubMed ID: 19166686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.
    Daemen J; Simoons ML; Wijns W; Bagust A; Bos G; Bowen JM; Braunwald E; Camenzind E; Chevaliers B; DiMario C; Fajadeto J; Gitt A; Guagliumi G; Hillege HL; James S; Jüni P; Kastrati A; Kloth S; Kristensen SD; Krucoff M; Legrand V; Pfisterer M; Rothman M; Serruys PW; Silber S; Steg PG; Tariah I; Wallentin L; Windecker SW; Aimonetti A; Allocco D; Berenger M; Boam A; Calle JP; Campo G; Carlier S; de Schepper J; Di Bisceglie G; Dobbels H; Farb A; Ghislain JC; Hellbardt S; ten Hoedt R; Isaia C; de Jong P; Lekehal M; LeNarz L; Mhullain FN; Nagai H; Patteet A; Paunovic D; Potgieter A; Purdy I; Raveau-Landon C; Ternstrom S; Van Wuytswinkel J; Waliszewski M;
    EuroIntervention; 2009 Jan; 4(4):427-36. PubMed ID: 19284063
    [No Abstract]   [Full Text] [Related]  

  • 13. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year clinical outcome after successful implantation of drug-eluting and bare metal stents in diabetic patients: results from a real-world single center registry.
    Dou KF; Xu B; Yang YJ; Chen JL; Qiao SB; Li JJ; Qin XW; Liu HB; Wu YJ; Chen J; Yao M; You SJ; Yuan JQ; Dai J; Gao RL
    Chin Med J (Engl); 2009 Mar; 122(6):612-6. PubMed ID: 19323921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical benefit of drug-eluting stents over bare-metal stents in diabetic patients with de novo left main coronary artery disease: results from a real-world multicenter registry.
    Capodanno D; Di Salvo ME; Palmerini T; Sheiban I; Margheri M; Vecchi G; Sangiorgi G; Piovaccari G; Bartorelli A; Briguori C; Ardissino D; Di Pede F; Ramondo A; Inglese L; Petronio AS; Bolognese L; Benassi A; Palmieri C; Filippone V; De Servi S; Tamburino C
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):310-6. PubMed ID: 19214964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance.
    Messori A; Trippoli S
    Heart; 2009 May; 95(10):847. PubMed ID: 19401286
    [No Abstract]   [Full Text] [Related]  

  • 20. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.